Artivion, Inc. (NYSE:AORT) CFO Lance A. Berry Sells 3,259 Shares

Artivion, Inc. (NYSE:AORT) CFO Lance A. Berry sold 3,259 shares of the company’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $27.31, for a total value of $89,003.29. Following the sale, the chief financial officer now owns 75,805 shares of the company’s stock, valued at approximately $2,070,234.55. The trade was a 4.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Artivion Trading Down 0.5 %

Shares of AORT stock opened at $25.44 on Thursday. Artivion, Inc. has a 1-year low of $18.38 and a 1-year high of $32.33. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. The stock has a 50-day moving average of $29.68 and a 200-day moving average of $27.83. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -1,272.00 and a beta of 1.75.

Artivion (NYSE:AORT) last announced its earnings results on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The business had revenue of $97.31 million for the quarter, compared to the consensus estimate of $100.82 million. On average, equities research analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Oppenheimer upped their target price on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and issued a $33.00 target price on shares of Artivion in a report on Tuesday, December 10th. Stifel Nicolaus lowered their target price on Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Needham & Company LLC lowered their target price on Artivion from $34.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $31.40.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC boosted its holdings in Artivion by 236.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock worth $32,000 after acquiring an additional 786 shares in the last quarter. Quarry LP boosted its holdings in Artivion by 210.8% in the third quarter. Quarry LP now owns 1,209 shares of the company’s stock worth $32,000 after acquiring an additional 820 shares in the last quarter. R Squared Ltd bought a new position in Artivion in the fourth quarter worth approximately $39,000. Arcadia Investment Management Corp MI bought a new position in Artivion in the fourth quarter worth approximately $43,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Artivion in the fourth quarter worth approximately $64,000. Institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.